Ms Kate Buccilli
Operations Manager, Ultra High Risk for Psychosis Research Program
Centre for Youth Mental Health (Orygen)
13 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
DOI: 10.1038/s41537-025-00622-02025
Journal article
Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11
DOI: 10.1093/schbul/sbae1492025
Journal article
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
DOI: 10.1038/s41537-025-00578-12025
Journal article
Enabling FAIR data stewardship in complex international multi-site studies: Data Operations for the Accelerating Medicines Partnership® Schizophrenia Program
DOI: 10.1038/s41537-025-00560-x2025
Journal article
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program
DOI: 10.1093/schizbullopen/sgaf0132025
Journal article
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program
DOI: 10.1093/schizbullopen/sgaf0122025
Journal article
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
DOI: 10.1038/s41537-025-00556-7
RECENT SCHOLARLY WORKS
2024
Journal article
Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis
DOI: 10.1016/j.psychres.2024.1159662024
Journal article
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
DOI: 10.1093/schbul/sbae0112024
Journal article
Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS
DOI: 10.1111/eip.13457